Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

22.73B

Market cap22.73B

Price-Earnings ratio

15.21

Price-Earnings ratio15.21

Dividend yield

—

Dividend yield—

Average volume

2.31M

Average volume2.31M

High today

$115.56

High today$115.56

Low today

$108.00

Low today$108.00

Open price

$109.95

Open price$109.95

Volume

3.80M

Volume3.80M

52 Week high

$115.56

52 Week high$115.56

52 Week low

$66.83

52 Week low$66.83

Stock Snapshot

With a market cap of 22.73B, Incyte(INCY) trades at $113.92. The stock has a price-to-earnings ratio of 15.21.

On 2026-06-27, Incyte(INCY) stock moved within a range of $108.00 to $115.56. With shares now at $113.92, the stock is trading +5.5% above its intraday low and -1.4% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 3.8M, versus its average volume of 2.31M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $115.56 and a low of $66.83.

INCY News

TipRanks 18h

Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know

Incyte (INCY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...

TipRanks 23h

Incyte announces positive CHMP opinion of Opzelura Cream

Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the...

TipRanks 1d

Incyte price target raised to $113 from $103 at UBS

UBS raised the firm’s price target on Incyte (INCY) to $113 from $103 and keeps a Neutral rating on the shares. The firm sees biopharma value stocks such as Inc...

Analyst ratings

59%

of 29 ratings

Buy

37.9%

Hold

58.6%

Sell

3.4%

More INCY News

Simply Wall St 1d

Incyte Lands Fresh Clinical Wins, Is It Fully Valued?

Incyte (INCY) stock is drawing fresh attention after a run of clinical and regulatory updates, including pivotal lymphoma data, positive rare disease results, e...

Simply Wall St 4d

What Incyte's Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

In mid-June 2026, Mirum Pharmaceuticals and Incyte reported pivotal PROGRESS Phase 2 data and an FDA Priority Review for zilurgisertib in ultra-rare fibrodyspla...

TipRanks 5d

Incyte Resolves Opzelura Medicaid Dispute, Gains One-Time Benefit

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 5d

Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks

In a report released today, Evan Seigerman from BMO Capital upgraded Incyte to a Hold, with a price target of $94.00. Claim 55% Off TipRanks Unlock powerful inv...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.